vimarsana.com

Latest Breaking News On - Charles consultants - Page 7 : vimarsana.com

Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary

- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic analysis by founders Professor Adam Mead

Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary

Macomics Ltd: Macomics, the Macrophage-based Drug Discovery company, secures £4 24m expansion financing, and appoints CEO, CSO and VP Immunology

(0) Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.

ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australias WEHI

Posted on 539 ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has entered into an exclusive global patent license agreement with Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI) providing rights to CISH KO in the field of NK cells for the treatment of cancer. “Deletion of CISH in NK cells leads to an improved metabolic profile, greatly enhances their proliferation, cytotoxicity, and persistence. In-vivo models of cancer have shown that CISH KO NK cells are much more efficient in eliminating cancer cells, making such cells a very attractive prospect for future clinical development,” said Prof Michael O’Dwyer, CSO of ONK Therapeutics.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.